Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Dow
Chinese Patent Office
QuintilesIMS
Healthtrust
US Army
Cantor Fitzgerald
Johnson and Johnson
Baxter

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,566,705

« Back to Dashboard

Which drugs does patent 7,566,705 protect, and when does it expire?

Patent 7,566,705 protects DULERA and is included in one NDA.

This patent has thirty-four patent family members in twenty-six countries.
Summary for Patent: 7,566,705
Title:Combination of formoterol and mometasone furoate for asthma
Abstract:A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
Inventor(s): Hassan; Ian F (Morris Plains, NJ), Clarke; Jeremy G (Bath, GB), Danahay; Henry L (Horsham, GB)
Assignee: Novartis AG (Basel, CH)
Application Number:11/199,291
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form; Device;

Drugs Protected by US Patent 7,566,705

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme DULERA formoterol fumarate; mometasone furoate AEROSOL, METERED;INHALATION 022518-001 Jun 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF ASTHMA ➤ Try a Free Trial
Merck Sharp Dohme DULERA formoterol fumarate; mometasone furoate AEROSOL, METERED;INHALATION 022518-002 Jun 22, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF ASTHMA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,566,705

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9904919.9Mar 03, 1999

Non-Orange Book US Patents Family Members for Patent 7,566,705

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,067,502 Combinations of formoterol and mometasone furoate for asthma ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,566,705

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2362499 ➤ Try a Free Trial
Chile 2004001170 ➤ Try a Free Trial
China 1341017 ➤ Try a Free Trial
China 1196478 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chubb
Chinese Patent Office
Federal Trade Commission
Julphar
Cantor Fitzgerald
Harvard Business School
Cerilliant
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.